Brooklyn Hospital Center

This document represents the first collaboration between 2 organizations-the American Society for Parenteral and Enteral Nutrition and the Society of Critical Care Medicine-to describe best practices in nutrition therapy in critically ill children. The target of these guidelines is intended to be the pediatric critically ill patient (>1 month and <18 years) expected to require a length of stay >2-3 days in a PICU admitting medical, surgical, and cardiac patients. In total, 2032 citations were scanned for relevance. The PubMed/MEDLINE search resulted in 960 citations for clinical trials and 925 citations for cohort studies. The EMBASE search for clinical trials culled 1661 citations. In total, the search for clinical trials yielded 1107 citations, whereas the cohort search yielded 925. After careful review, 16 randomized controlled trials and 37 cohort studies appeared to answer 1 of the 8 preidentified question groups for this guideline. We used the GRADE criteria (Grading of Recommendations, Assessment, Development, and Evaluation) to adjust the evidence grade based on assessment of the quality of study design and execution. These guidelines are not intended for neonates or adult patients. The guidelines reiterate the importance of nutrition assessment-particularly, the detection of malnourished patients who are most vulnerable and therefore may benefit from timely intervention. There is a need for renewed focus on accurate estimation of energy needs and attention to optimizing protein intake. Indirect calorimetry, where feasible, and cautious use of estimating equations and increased surveillance for unintended caloric underfeeding and overfeeding are recommended. Optimal protein intake and its correlation with clinical outcomes are areas of great interest. The optimal route and timing of nutrient delivery are areas of intense debate and investigations. Enteral nutrition remains the preferred route for nutrient delivery. Several strategies to optimize enteral nutrition during critical illness have emerged. The role of supplemental parenteral nutrition has been highlighted, and a delayed approach appears to be beneficial. Immunonutrition cannot be currently recommended. Overall, the pediatric critical care population is heterogeneous, and a nuanced approach to individualizing nutrition support with the aim of improving clinical outcomes is necessary.

SCCM) in Critical Care Medicine, 2009; volume 37, number 5. literature were resolved by consensus of opinion of the committee members, which in some cases led to a downgrade of the recommendation.Following an extensive review process by external reviewers, the final guideline manuscript was reviewed and approved by A.S.P.E.N.

PRELIMINARY REMARKS (INTENT OF GUIDELINES) A.S.P.E.N. and SCCM are both nonprofit organizations composed of multidisciplinary healthcare professionals. The mission of A.S.P.E.N. is to improve patient care by advancing the science and practice of clinical nutrition and metabolism. The mission of SCCM is to secure the highest quality care for all critically ill and injured patients. Guideline Limitations: These A.S.P.E.N.−SCCM Clinical Guidelines are based on general conclusions of health professionals who, in developing such guidelines, have balanced potential benefits to be derived from a particular mode of medical therapy against certain risks inherent with such therapy. However, practice guidelines are not intended as absolute requirements. The use of these practice guidelines does not in any way project or guarantee any specific benefit in outcome or survival. The judgment of the healthcare professional based on individual circumstances of the patient must always take precedence over the recommendations in these guidelines. The guidelines offer basic recommendations that are supported by review and analysis of the current literature, other national and international guidelines, and a blend of expert opinion and clinical practicality. The population of critically ill patients in an intensive care unit (ICU) is not homogeneous. Many of the studies on which the guidelines are based are limited by sample size, patient heterogeneity, variability in disease severity, lack of baseline nutritional status, and insufficient statistical power for analysis. Periodic Guideline Review and Update: This particular report is an update and expansion of guidelines published by A.S.P.E.N. and SCCM in 2009 (1). Governing bodies of both A.S.P.E.N. and SCCM have mandated that these guidelines be updated every three to five years. The database of randomized controlled trials (RCTs) that served as the platform for the analysis of the literature was assembled in a joint “harmonization process” with the Canadian Clinical Guidelines group. Once completed, each group operated separately in their interpretation of the studies and derivation of guideline recommendations (2). The current A.S.P.E.N. and SCCM guidelines included in this paper were derived from data obtained via literature searches by the authors through December 31, 2013. Although the committee was aware of landmark studies published after this date, these data were not included in this manuscript. The process by which the literature was evaluated necessitated a common end date for the search review. Adding a last-minute landmark trial would have introduced bias unless a formalized literature search was re-conducted for all sections of the manuscript. Target Patient Population for Guideline: The target of these guidelines is intended to be the adult (≥ 18 years) critically ill patient expected to require a length of stay (LOS) greater than 2 or 3 days in a medical ICU (MICU) or surgical ICU (SICU). The current guidelines were expanded to include a number of additional subsets of patients who met the above criteria, but were not included in the previous 2009 guidelines. Specific patient populations addressed by these expanded and updated guidelines include organ failure (pulmonary, renal, and liver), acute pancreatitis, surgical subsets (trauma, traumatic brain injury [TBI], open abdomen [OA], and burns), sepsis, postoperative major surgery, chronic critically ill, and critically ill obese. These guidelines are directed toward generalized patient populations but, like any other management strategy in the ICU, nutrition therapy should be tailored to the individual patient. Target Audience: The intended use of these guidelines is for all healthcare providers involved in nutrition therapy of the critically ill, primarily physicians, nurses, dietitians, and pharmacists. Methodology: The authors compiled clinical questions reflecting key management issues in nutrition therapy. A committee of multidisciplinary experts in clinical nutrition composed of physicians, nurses, pharmacists, and dietitians was jointly convened by the two societies. Literature searches were then performed using key words (critically ill, critical care, intensive care, nutrition, enteral, parenteral, tube feeding, and those related to assigned topics such as pancreatitis, sepsis, etc.) to evaluate the quality of evidence supporting a response to those questions, which were then used to derive a subsequent treatment recommendation. The literature search included MEDLINE, PubMed, Cochrane Database of Systemic Reviews, the National Guidelines Clearing House and an Internet search using the Google search engine for scholarly articles through an end date of December 31, 2013 (including ePub publications). While preference was given to RCTs, other forms of resource material were used to support the response, including nonrandomized cohort trials, prospective observational studies, and retrospective case series. Use of publications was limited to full-text articles available in English on adult humans. For all included RCTs, two readers completed data abstraction forms (DAFs) examining the data and assessing the quality of the research methodology to produce a shared evaluation achieved by consensus for each study (example of DAF provided in the supplemental data, Supplemental Digital Content 1, https://links.lww.com/CCM/B571). DAFs were constructed only for RCTs. When the strongest available evidence was a published meta-analysis, the studies from the meta-analysis were used to determine the quality of the evidence and assessed by two evidence assessors. The data from included trials were entered into Review Manager 5.2 software to create forest plots aggregating the effect size for each intervention and outcome (3). The key forest plots supporting the recommendation are included throughout the text and in the supplement data (Supplemental Digital Content 1, https://links.lww.com/CCM/B571). No new forest plots were created when a meta-analysis was evaluated. Since release of the 2009 A.S.P.E.N. and SCCM Clinical Guidelines, the concepts of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group have A of the methodology published The data from the Review Manager analysis was to software the of evidence for a given intervention and outcome was evaluated for created each that was then by a The are provided in the supplement data (Supplemental Digital Content 1, https://links.lww.com/CCM/B571). to the number of observational studies were critically but not to the However, in the observational studies were the only available evidence in a their quality of evidence was using When or observational study was available to a consensus of the group on the clinical practice was and the recommendation was on expert of recommendation for clinical practice was based on both the available evidence and the risks and benefits to patients. While each recommendation and provided the supporting a by the group and every committee was for their with the recommendation. of consensus was of authors with a particular recommendation. recommendation not this of with a consensus of other recommendations a of of or with all A.S.P.E.N. and SCCM clinical guidelines, this was to review by clinical experts from all the practice that would use the guidelines, both and to the A of the guidelines is in the supplement data (Supplemental Digital Content 1, https://links.lww.com/CCM/B571). A nutrition based on the guidelines on by the for the is in OF authors completed both an A.S.P.E.N. and SCCM of for and was or from were any any of the committee to the of nutrition by nutrition by therapy to of or and to as The of nutrition in the the be is with a in which patients a response with of organ and the three have in the of the and of in in the critically ill nutrition support in the critically ill population was as care to to and support the patient throughout the this strategy to nutrition in which the is to the response to and in the clinical of critical be achieved by and and nutrition support primarily by the is as a strategy that disease severity, in the ICU, and patient the use of a nutrition patients who benefit from nutrition on expert a of nutrition be performed on all patients to the ICU for is to be nutrition those patients to benefit from therapy. have with by critical that to of nutrition and However, in the critically ill always to international consensus group to the of of baseline nutrition have by A.S.P.E.N. and the of and the other nutrition is and by evaluation of baseline nutrition and of disease patients are to an nutrition of However, patients nutrition in an ICU require a nutrition Many and are used to evaluate nutrition status, such as the the the the and the However, only the and the determine both nutrition and disease Although both were based on retrospective have used to nutrition in in critically ill patients are by an 3 and those with a or a is not is available as a for the a nutrition prospective nonrandomized studies that patients nutrition are to benefit from with outcome and than patients nutrition While use and evidence is to date, in these their in the by as to the of and in the additional or when nutrition in critically ill adult on expert that nutritional include an evaluation of of the and of not using nutrition or as are not in critical the critical care the are a of the acute response in and of and not nutrition in the ICU are not in of nutrition or of nutrition therapy of and are and should not be used as is as a to and determine in in the ICU, given of use and A a of and is unless a for other is used to determine be to into nutrition and studies in ICU patients are of is in and are for use in critically ill and be of in the is the for in the critically ill adult that be used to determine when available and in the of that the of of on expert in the of that a published or a be used to determine requirements. for should determine in to the of nutrition therapy. be through published or The of be limited by and in the ICU that the and of include the of or supplemental and therapy and than have published in the literature, with from when to and as in an ICU are in and patients derived from patients are than derived from The of is related to in the critically ill such as and The only of using over other is However, in critically ill patients or in the of or should use or in these provided by and such as should be for when nutrition therapy to target as by to to nutrition While two that met data from that of and were provided in study patients to nutrition therapy was directed by issues with study a recommendation for use of a study of use of nutrition therapy the the of in therapy was directed by the and were but outcome were not evaluated A study in general ICU patients used both and to target by or a While the was than the obtained by only study patients were by an ICU were by of care ICU which to and in the study patients. The toward in study patients to is to in of their with to ICU and of by or by should be than and to and should be used be from in critically ill adult on expert an evaluation of of be the critical care to be the for supporting and For critically ill are than and are not met by of have a with to benefit from The to should be based on an of of be used to of by the of to that when studies are not available to are not for of and should not be used in the critical care in this is the benefit of in critically ill adult patients to or this that nutrition support therapy in the of be in the critically ill patient who is to of the of the by the and the release of as and by and supporting the of and that the and in to such as the and in from of is a that is of the major or The of the include of with for and greater of organ disease in are and the of is to outcome of organ and The specific for are to and the response, and disease of therapy include use of the as a for the of and use of as an for previous data from meta-analysis of trials by a toward when was to of after that A meta-analysis of trials by in and when was on of ICU A meta-analysis of trials by a in and but in organ failure when was of to the ICU, to after that an updated meta-analysis of that met the of all on with on of was with a in and to or nutrition nutrition a in outcome the use of or for adult critically ill the use of over in critically ill patients who require nutrition support therapy. of to the of critically ill patients is and to use of The of to are in a of patient populations in critical including major surgery, and acute While studies have a effect on the outcome effect from is a in and in patient and in and ICU previous to in with use of and were with use of to in of the by of the in the two of nutrition support therapy meta-analysis by a a of with use of to studies patients that met criteria, on which was to be with than ICU was with to by to and were not These in outcome from the of from studies and in the with in medical management and new nutrition nutrition the clinical evidence of to in critically ill adult on expert in the of and patient should be evaluated when of should not be to of The literature the that and evidence of or are not for of in the ICU in of on the and of ICU and postoperative are related to of the and of or etc.) and to in to of patients on are only of and not to or The for of the of is based on studies of which critically ill surgical the and of the of to the or greater disease and with have to have ICU than those with or ICU to with greater number of of days when to days with of of is with a greater number of of A greater number of of as is and clinical is the of of the for critically ill does the of of patient that the of be in the in those critically ill patients for or those who have to of to on expert consensus in critically ill is to in the therapy in the is and the to of The of of the of the tube is in the of the or or the the be by patient ICU and of and the to in critically ill in clinical including and of the data from the that met criteria, trials on with and trials a of to Although the of is in or and of is not via the benefit than nutritional of in adult critically ill on expert that in the of or should be the patient is of be with in patients of the of critical is provided to patients who are to sepsis, and and are for the is a with a retrospective review of patients of those patients of ICU and than those The effect of was in patients with When were for by for was with While be provided with to patients on of should be in patients who are in patients for are or in patients for are to For patients on therapy any of tube or of and should be as of and should be and OF population of patients in the ICU does not require nutrition support therapy over the of on expert that patients who are nutrition with baseline nutrition and disease 3 or who require nutrition therapy over the of in the to the ICU are a group with of nutrition and disease patients with nutrition baseline nutrition status, and disease by an of 3 or a are in the ICU for than a When these patients should be to to nutrition status, and organ Clinical trials of nutrition therapy in critically ill patients of patients with of the of that a lack of nutrition is in not and of in patients who potential of in the ICU patient population any benefit in the in However, patients and their nutrition and disease patients should be their disease severity, or expected the then of therapy. For which population of patients in the ICU is to over the of that or nutrition by is for patients with acute injury and those expected to have a of as these two of have patient over the of of randomized study of a population of patients with acute failure and randomized trial patients with and those expected to have a of of as or to for to days in a of over the of in the ICU than in clinical including and of to to based on The trial for of and the that study patients were critically ill and a in the ICU, nutrition is a lack of data available to determine the benefit of of those patients to be nutrition These patients were in the For these review population of patients in the ICU as to target nutrition in the of should target nutrition be in these on expert that patients who are nutrition or or should be toward as as over for to of or and should be in to the clinical benefit of over the of as or be to and in to but be insufficient to the for therapy in patients. that of be to in and in and to of in injury and to in patients a prospective nonrandomized that patients who nutrition therapy for in and to patients who insufficient therapy No were and insufficient in patients a observational for ICU patients with the of as of with in The was achieved with which provided For was and the of provided a in clinical of adult critically ill that should be are expected to be in the of and be in or patients sections and of studies in critical that of is to than of of the other of and the of by critically ill patients to be than A prospective observational study in patients that of both and was with a in in was when were met prospective observational study in a ICU, a in was with Group Group RCTs, in when a was provided of in the critical care with using Use of or to is of limited in the ICU OF should of be in the adult critically ill on expert that patients should be for of that of should be that a of for the patient the of or should be to of and to be by of and and of patient such as or is by of of and or that than of assessed by for as and than of patients their target their ICU A number of the of in the critical care providers who to only of requirements. of is This of and in patients on only of target from to the of in over of patients for an of of the for which are in of and of all While patient for a of only of this after for and of ICU patients and for to of issues the such as or the for to of patients randomized to surgical general than those patients for was for each be by and for which patients are be used as a for to ICU patients on that not be used as of care to ICU patients on for those are for in the of other of should be of not with of or Although a study that of over with using studies and three other trials using the of every to a trial using a and specific for a of were to be a for with a of a of and a of from that the for to of from a number of to a number of does not the of or the for does not the patient from these Use of to of of and of healthcare and outcome through of studies have that the practice of using of patient three trials, two and prospective trial with to of the trials greater by of or greater in trial but when were a trial in the practice of is a number of be used to critically ill patients on review of and evaluation of clinical for should be and to of should be sections and For those to using care should be in their in the of should and to the of to of but of should not for in the of other of be used in the adult ICU that be and to the of of to on expert that use of a or a be Use of or that and specific for of and or which be or have to be in the of provided in which or are of have to of nutrition These to to for is use the of of to and of individual as over the days of use in with and tube other with in patients who lack of the data from two studies that met use of to patient outcome by the of to was used of be assessed in critically ill patients and be to the of on expert that patients on should be assessed for of and that to of and should be is of the of for be by a number of including to the of a over of care, of the ICU, and use of and of the is with of than and of the of by in patients to be for of to the of of from the to the to the of and was in patients with including when to studies using evidence of to patients on was in ICU of or to on expert that for patients or those to be to of should be to The potential from of to of was in study a toward with to have greater with in of with but with to patient outcome in patients of to such as or be of Adding such as or to improve and of but in in clinical outcome for ICU patients. A of that met using and with were by No was in of or However, were with than with in three that met of have to a to be for to be in patients with For both and be with including and and should be used with including in the have with to therapy with and for greater were the of was in patients therapy clinical from therapy in of are this be Use of through the the of the of the in to improve was in study to the of and the of to and have to of after to date are studies their use as on expert that to of and be all ICU patients the of the should be and use of a should be the of the was in study to the of from to to health with was in two studies to and in patients While studies the use of in general ICU populations have outcome two studies in which care was included in in to would include the of when and of the ICU for and in in the critical care on expert that any be used as a for of on expert that not be used as for in the critical care for are use of a with other such as and have to and with an for was to be with and patient The and through a a against the use of as a for in patients on The basic for the use of in is related to of to be and use is by should with be assessed in the adult critically ill on expert that be for but that be the of in an ICU patient to determine in ICU patients is common but be as the from and in and to the with nutrition in and for the of in clinical the used are or of The to acute and of in of and in and including have an and and and as are and by with a of a in the patient is that have a effect on of are and of should include an of for evaluate for or and review of should be to from OF should be used when in the critically ill on expert using a when in the ICU the use of all in critically ill patients in a and in the For the of patients in an ICU a or to is and be This recommendation is of in that benefit to patient outcome in the literature for the use of in a general ICU including those that are to be disease specific organ specific (pulmonary, renal, or would be the use of an in the postoperative patient in a Use of outcome benefits over in a The for to to to be only with and their of and be used in a of patients on a to benefits such as and have an on clinical for the critically ill patient of the ICU with other including and should not be used in the for these should be for patients with and patients in the sections and of with and for the critically ill the must the patient is a for a While outcome benefits of and of with use of such in a general ICU medical and only a in to in a A meta-analysis of that met that to the have a in the critically ill but the data in the population not support any recommendation for use in of studies, studies, or studies, studies have addressed the individual their specific or their This of literature for the of studies, performed in a of ICU patient with a of and are as or but in their and of individual and are is not the data from published studies be to use of with that have not evaluated. on the of the populations and the in the the Guidelines that recommendation of support in the was with and be used in patients with or a recommendation this the use of an by an and in patients with and given of to have evaluated the use of or with an and in patients with and These studies have based on the of the used in the study by an of with study patients of to a in the for the effect of a in two of the studies all trials based on that use of and does not ICU of organ or to use of a this in of the data, the Guidelines that a with an in patients be used data are adult critically ill are the for or that a not be used in the adult critically ill patient to or of on expert use of a is evidence of both and in patients for or use of in the patient with with or lack of response to patients with other of have such as and benefit from use of a a or a supplement to a are both and of a available in a patient be in a critical care

BACKGROUND: A program for banking, characterizing, and distributing placental blood, also called umbilical-cord blood, for transplantation provided grafts for 562 patients between August 24, 1992, and January 30, 1998. We evaluated this experience. METHODS: Placental blood was stored under liquid nitrogen and selected for specific patients on the basis of HLA type and leukocyte content. Patients were prepared for the transplantation of allogeneic hematopoietic cells in the placental blood and received prophylaxis against graft-versus-host disease (GVHD) according to routine procedures at each center. RESULTS: Outcomes at 100 days after transplantation were known for all 562 patients, and outcomes at 1 year for 94 percent of eligible recipients. The cumulative rates of engraftment among the recipients, according to actuarial analysis, were 81 percent by day 42 for neutrophils (median time to engraftment, 28 days) and 85 percent by day 180 for platelets (median, day 90). The speed of myeloid engraftment was associated primarily with the leukocyte content of the graft, whereas transplantation-related events were associated with the patient's underlying disease and age, the number of leukocytes in the graft, the degree of HLA disparity, and the transplantation center. After engraftment, age, HLA disparity, and center were the primary predictors of outcome. Severe acute GVHD (grade III or IV) occurred in 23 percent of patients, and chronic GVHD occurred in 25 percent. The rate of relapse among recipients with leukemia was 9 percent within the first 100 days, 17 percent within 6 months, and 26 percent by 1 year. These rates were associated with the severity of GVHD, type of leukemia, and stage of the disease. CONCLUSIONS: Placental blood is a useful source of allogeneic hematopoietic stem cells for bone marrow reconstitution.

BACKGROUND: Medical care for very low birth weight (VLBW) infants and their mothers has changed dramatically during the 1990s, yet it is unclear how these changes have affected mortality and morbidity. OBJECTIVE: We used the Vermont Oxford Network Database to identify trends in clinical practice and patient outcomes for VLBW infants born from 1991 to 1999. METHODS: Logistic regression was used to evaluate temporal trends in practices and outcomes while adjusting for patient characteristics and accounting for clustering of cases within hospitals. RESULTS: There were 118 448 infants 501 to 1500 g from 362 neonatal intensive care units enrolled in the Network Database from 1991 to 1999. Prenatal care, cesarean section, multiple births, antenatal steroids, and 1-minute Apgar scores increased during this period, as did the use of nasal continuous positive airway pressure, high-frequency ventilation, surfactant, and postnatal steroids. The proportion of white infants decreased; the proportions of Hispanic infants and those of other races increased. The crude and adjusted rates of mortality, pneumothorax, intraventricular hemorrhage (IVH), and severe IVH declined from 1991 to 1995, whereas from 1995 to 1999, the rates of mortality, IVH, and severe IVH did not change significantly, and pneumothorax increased. CONCLUSIONS: There have been major changes in both obstetric and neonatal care during the 1990s. These changes were associated with decreases in mortality and morbidity for VLBW infants during the first half of the decade. However, since 1995, no additional improvements in mortality or morbidity have been seen, ending a decades-long trend of improving outcomes for these infants.

BACKGROUND: Oxidative stress contributes to the complex pathophysiology of sickle cell disease. Oral therapy with pharmaceutical-grade l-glutamine (USAN, glutamine) has been shown to increase the proportion of the reduced form of nicotinamide adenine dinucleotides in sickle cell erythrocytes, which probably reduces oxidative stress and could result in fewer episodes of sickle cell-related pain. METHODS: -thalassemia and a history of two or more pain crises during the previous year. Patients who were receiving hydroxyurea at a dose that had been stable for at least 3 months before screening continued that therapy through the 48-week treatment period. RESULTS: A total of 230 patients (age range, 5 to 58 years; 53.9% female) were randomly assigned, in a 2:1 ratio, to receive l-glutamine (152 patients) or placebo (78 patients). The patients in the l-glutamine group had significantly fewer pain crises than those in the placebo group (P=0.005), with a median of 3.0 in the l-glutamine group and 4.0 in the placebo group. Fewer hospitalizations occurred in the l-glutamine group than in the placebo group (P=0.005), with a median of 2.0 in the l-glutamine group and 3.0 in the placebo group. Two thirds of the patients in both trial groups received concomitant hydroxyurea. Low-grade nausea, noncardiac chest pain, fatigue, and musculoskeletal pain occurred more frequently in the l-glutamine group than in the placebo group. CONCLUSIONS: Among children and adults with sickle cell anemia, the median number of pain crises over 48 weeks was lower among those who received oral therapy with l-glutamine, administered alone or with hydroxyurea, than among those who received placebo, with or without hydroxyurea. (Funded by Emmaus Medical; ClinicalTrials.gov number, NCT01179217 .).

Philip G. Cabaud, M.D., Felix Wróblewski, M.D., With the Technical Assistance ok, Vincent Ruggiero; Colorimetric Measurement of Lactic Dehydrogenase Activi

Mexico harbors great cultural and ethnic diversity, yet fine-scale patterns of human genome-wide variation from this region remain largely uncharacterized. We studied genomic variation within Mexico from over 1000 individuals representing 20 indigenous and 11 mestizo populations. We found striking genetic stratification among indigenous populations within Mexico at varying degrees of geographic isolation. Some groups were as differentiated as Europeans are from East Asians. Pre-Columbian genetic substructure is recapitulated in the indigenous ancestry of admixed mestizo individuals across the country. Furthermore, two independently phenotyped cohorts of Mexicans and Mexican Americans showed a significant association between subcontinental ancestry and lung function. Thus, accounting for fine-scale ancestry patterns is critical for medical and population genetic studies within Mexico, in Mexican-descent populations, and likely in many other populations worldwide.

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver responsible for an increasing number of cancer-related deaths, especially in developing economies of Asia and Africa. A plethora of risk factors have been described in the literature. Some of the important ones include chronic viral hepatitis, liver cirrhosis, environmental toxins such as aflatoxin, non-alcoholic fatty liver disease, lifestyle factors like alcohol consumption, smoking, and dietary factors, metabolic diseases like diabetes mellitus and obesity, and genetic and hereditary disorders. The development of HCC is complex involving sustained inflammatory damage leading to hepatocyte necrosis, regeneration, and fibrotic deposition. It also poses multiple challenges in diagnosis and treatment despite advances in diagnostic, surgical, and other therapeutic advancements. This is a narrative review of findings of multiple studies that were retrieved from electronic databases like PubMed, MEDLINE, Embase, Google Scholar, Scopus, and Cochrane. We summarise the current knowledge regarding the epidemiology and various risk factors for the development of HCC with a brief note on various prevention strategies.

OBJECTIVE: The study sought to determine if there were race/ethnicity or gender differences in access to coronary artery bypass graft (CABG) surgery among patients who have been designated as appropriate and as necessary for that surgery according to the RAND methodology. METHODS: RAND appropriateness and necessity criteria were used to identify a race/gender stratified sample of postangiography patients who would benefit from coronary artery bypass graft surgery. These patients were tracked for 3 months to determine if they had undergone coronary artery bypass graft surgery in New York State. Subjects were a total of 1,261 postangiography patients in eight New York hospitals in 1994 to 1996. Measures included percentages of patients for whom coronary artery bypass graft surgery was appropriate and necessary undergoing surgery by race/ethnicity and gender, as well as multivariate odds ratios for race/ethnicity and gender. RESULTS: After controlling for age, payer, number of vessels diseased, and presence of left main disease, African-American and Hispanic patients were found to be significantly less likely to undergo coronary artery bypass graft surgery than white non-Hispanic patients (respective odds ratios 0.64 and 0.60). When "necessity" was used as a criterion instead of "appropriateness," significant differences in access for African-American patients remained. The gatekeeper physician recommended surgery only 10% of the time that patients did not undergo "appropriate" coronary artery bypass graft surgery, and this percentage did not vary significantly by race/ethnicity or gender of the patient. CONCLUSIONS: Even after controlling for appropriateness and necessity for coronary artery bypass graft surgery in a prospective study, African-American patients had significant access problems in obtaining coronary artery bypass graft surgery. These problems appeared not to be related to patient refusals.

UNLABELLED: A spontaneous inflammatory disease in rats transgenic for HLA-B27 resembles the B27-associated human spondyloarthropathies. Colitis and arthritis, the two most important features, require T cells, gut bacteria, and high expression of B27 in bone marrow-derived cells. Control rats with HLA-B7 remain healthy. Most rats with HLA-Cw6 (associated with psoriasis vulgaris) remain healthy; a minority develop mild and transient disease. Rats with a mutant B27 with a Cys67-->Ser substitution resemble wild-type B27 transgenics, but with a lower prevalence of arthritis. A similar phenotype is seen in B27 rats co-expressing a viral peptide that binds B27. Disease-prone LEW but not F344 B27 rats develop high serum IgA levels concurrent with disease progression. Colitis is associated with high interferon-gamma, arthritis with high interleukin-6. Disease is similar in B27 LEW, F344, and PVG rats, but the DA background is protective. CONCLUSIONS: The spondyloarthropathy-like disease in rats is specific for HLA-B27 but does not require Cys67. Arthritis but not colitis is particularly sensitive to B27 peptide-binding specificity. Genetic background exerts a strong influence, but some phenotypic differences exist between permissive strains that do not influence disease susceptibility. The data favor a role for B27 peptide presentation in arthritis, but other mechanisms to explain the role of B27 have not been excluded.

BACKGROUND AND OBJECTIVE: Extremely low birth weight infants frequently receive red cell transfusions. We sought to determine whether a restrictive versus liberal hemoglobin transfusion threshold results in differences in death or adverse neurodevelopmental outcomes of extremely low birth weight infants. PATIENTS AND METHODS: Extremely low birth weight infants previously enrolled in the Preterm Infants in Need of Transfusion Trial, a randomized, controlled trial of low versus high hemoglobin transfusion thresholds, were followed up at 18 to 21 months' corrected age. Erythrocyte transfusion was determined by an algorithm of low (restrictive) or high (liberal) hemoglobin transfusion thresholds, differing by 10 to 20 g/L and maintained until first hospital discharge. The primary composite outcome was death or the presence of cerebral palsy, cognitive delay, or severe visual or hearing impairment. RESULTS: Of 451 enrolled infants, the primary outcome was available in 430. There was no statistically significant difference in the primary outcome, found in 94 (45%) of 208 in the restrictive group and 82 (38%) of 213 in the liberal group. There were no statistically significant differences in preplanned secondary outcomes. However, the difference in cognitive delay (Mental Development Index score < 70) approached statistical significance. A posthoc analysis with cognitive delay redefined (Mental Development Index score < 85) showed a significant difference favoring the liberal threshold group. CONCLUSIONS: Maintaining the hemoglobin of extremely low birth weight infants at these restrictive rather than liberal transfusion thresholds did not result in a statistically significant difference in combined death or severe adverse neurodevelopmental outcome.

Currently, accepted protocol which has been developed at the Prenatal Diagnosis Laboratory of New York City (PDL) requires that when a chromosome abnormality is found in one or more cells in one flask, another 20-40 cells must be examined from one or two additional flasks. Chromosome mosaicism is diagnosed only when an identical abnormality is detected in cells from two or more flasks. In a recent PDL series of 12,000 cases studied according to this protocol, we diagnosed 801 cases (6.68 per cent) of single-cell pseudomosaicism (SCPM), 126 cases (1.05 per cent) of multiple-cell pseudomosaicism (MCPM), and 24 cases (0.2 per cent) of true mosaicism. Pseudomosaicism (PM) involving a structural abnormality was a frequent finding (2/3 of SCPM and 3/5 of MCPM), with an unbalanced structural abnormality in 55 per cent of SCPM and 24 per cent of MCPM. We also reviewed all true mosaic cases (a total of 50) diagnosed in the first 22,000 PDL cases. Of these 50 cases, 23 were sex chromosome mosaics and 27 had autosomal mosaicism; 48 cases had numerical abnormalities and two had structural abnormalities. Twenty-five cases of mosaicism were diagnosed in the first 20 cells from two flasks, i.e., without additional work-up, whereas the other 25 cases required extensive work-up to establish a diagnosis (12 needed additional cell counts from the initial two culture flasks; 13 required harvesting a third flask for cell analysis). Our data plus review of other available data led us to conclude that rigorous efforts to diagnose true mosaicism have little impact in many instances, and therefore are not cost-effective. On the basis of all available data, a work-up for potential mosaicism involving a sex chromosome aneuploidy or structural abnormality should have less priority than a work-up for a common viable autosomal trisomy. We recommend revised guidelines for dealing with (1) a numerical versus a structural abnormality and (2) an autosomal versus a sex chromosome numerical aneuploidy. Emphasis should be placed on autosomes known to be associated with phenotypic abnormalities. These new guidelines, which cover both flask and in situ methods, should result in more effective prenatal cytogenetic diagnosis and reduced patient anxiety.

The African Diaspora in the Western Hemisphere represents one of the largest forced migrations in history and had a profound impact on genetic diversity in modern populations. To date, the fine-scale population structure of descendants of the African Diaspora remains largely uncharacterized. Here we present genetic variation from deeply sequenced genomes of 642 individuals from North and South American, Caribbean and West African populations, substantially increasing the lexicon of human genomic variation and suggesting much variation remains to be discovered in African-admixed populations in the Americas. We summarize genetic variation in these populations, quantifying the postcolonial sex-biased European gene flow across multiple regions. Moreover, we refine estimates on the burden of deleterious variants carried across populations and how this varies with African ancestry. Our data are an important resource for empowering disease mapping studies in African-admixed individuals and will facilitate gene discovery for diseases disproportionately affecting individuals of African ancestry.

Abstract Inflammatory breast cancer (IBC) is a highly aggressive form of breast cancer that displays profound cancer stem cell (CSC) and mesenchymal features that promote rapid metastasis. Another hallmark of IBC is high infiltration of M2 tumor-associated (immune-suppressing) macrophages. The molecular mechanism that drives these IBC phenotypes is not well understood. Using patient breast tumor specimens, breast cancer cell lines, and a patient-derived xenograft model of IBC, we demonstrate that IBC strongly expresses IL8 and growth-regulated oncogene (GRO) chemokines that activate STAT3, which promotes development of high levels of CSC-like cells and a mesenchymal phenotype. We also show that IBC expresses high levels of many monocyte recruitment and macrophage polarization factors that attract and differentiate monocytes into tumor-promoting, immune-suppressing M2-like macrophages. The M2 macrophages in turn were found to secrete high levels of IL8 and GRO chemokines, thereby creating a feed-forward chemokine loop that further drives an IBC epithelial-to-mesenchymal transition. Our study uncovers an intricate IBC-initiated autocrine–paracrine signaling network between IBC cells and monocytes that facilitates development of this highly aggressive form of breast cancer. Significance: This study uncovers a signaling network in which IBC cells commandeer macrophages to become tumor-promoting, and they in turn drive IBC cells to be more cancer stem-like, mesenchymal, and aggressive.

This case report examines a male with no previous history of seizures initially admitting to the medical service later upgraded to ICU after respiratory failure developing multiple episodes of seizures. Laboratory values on admission, neurological investigations, as well as review of current literature on COVID-19 encephalitis is provided.

There are limited and discordant results on the comparison between microwave ablation (MWA) and radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC). This meta-analysis aims to compare the two treatments in terms of efficacy and safety, based on a meta-analysis of randomized-controlled trials (RCTs). A computerized bibliographic search was performed on the main databases throughout August 2020. The primary outcome was the complete response rate, while survival rate (at 1-, 2-, 3-, and 5-year), disease-free survival rate (at 1-, 2-, 3-, and 5-year), local and distant recurrence rate, adverse event rate, and number of treatment sessions were the secondary outcomes. Seven RCTs enrolling 921 patients were included. No difference in terms of complete response between the two treatments was observed (risk ratio (RR) 1.01, 95% CI 0.99-1.02). Survival rates were constantly similar, with RRs ranging from 1.05 (0.96-1.15) at 1 year to 0.91 (0.81-1.03) at 5 years. While local recurrence rate was similar between MWA and RFA (RR 0.70, 0.43-1.14), distant recurrence rate was significantly lower with MWA (RR 0.60, 0.39-0.92). Disease-free survival at 1, 2, and 3 years was similar between the two groups with RR 1.00 (0.96-1.04), 0.94 (0.84-1.06), and 1.06 (0.93-1.21), respectively. On the other hand, RR for disease-free survival at 5 years was significantly in favor of MWA (3.66, 1.32-42.27). Adverse event rate was similar between the two treatments (RR 1.06, 0.48-2.34), with bleeding and hematoma representing the most frequent complications. Our results indicate a similar efficacy and safety profile between the two techniques. MWA seems to decrease the rate of long-term recurrences, but this finding needs to be confirmed in further trials.

Abstract Background We conducted this study to describe the clinical characteristics, microbiology, and outcomes of patients treated with ceftazidime-avibactam (CZA) for a range of multidrug-resistant Gram-negative (MDR-GN) infections. Methods This is a multicenter, retrospective cohort study conducted at 6 medical centers in the United States between 2015 and 2019. Adult patients who received CZA (≥72 hours) were eligible. The primary outcome was clinical failure defined as a composite of 30-day all-cause mortality, 30-day microbiological failure, and/or failure to resolve or improve signs or symptoms of infection on CZA. Results In total, data from 203 patients were evaluated. Carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas spp were isolated from 117 (57.6%) and 63 (31.0%) culture specimens, respectively. The most common infection sources were respiratory (37.4%), urinary (19.7%), and intra-abdominal (18.7%). Blood cultures were positive in 22 (10.8%) patients. Clinical failure, 30-day mortality, and 30-day recurrence occurred in 59 (29.1%), 35 (17.2%), and 12 (5.9%) patients, respectively. On therapy, CZA resistance developed in 1 of 62 patients with repeat testing. Primary bacteremia or respiratory tract infection and higher SOFA score were positively associated with clinical failure (adjusted odds ratio [aOR] = 2.270, 95% confidence interval [CI] = 1.115–4.620 and aOR = 1.234, 95% CI = 1.118–1.362, respectively). Receipt of CZA within 48 hours of infection onset was protective (aOR, 0.409; 95% CI, 0.180–0.930). Seventeen (8.4%) patients experienced a potential drug-related adverse effect (10 acute kidney injury, 3 Clostridioides difficile infection, 2 rash, and 1 each gastrointestinal intolerance and neutropenia) Conclusions Ceftazidime-avibactam is being used to treat a range of MDR-GN infections including Pseudomonas spp as well as CRE.

To determine the effect of human immunodeficiency virus (HIV) infection on cervical histology, 32 known HIV-seropositive women underwent cervical colposcopic evaluation. All had cervical cytology, colposcopically directed biopsy, and T-cell studies performed. Thirteen of 32 patients (41%) had cervical intraepithelial neoplasia (CIN). Another 14 of 32 patients (44%) had histologic evidence of cervicitis. Abnormal cytology, noted in only three women, suggested CIN in one and inflammatory atypia in two. All (five of five) patients with a clinical diagnosis of AIDS had CIN, compared with 30% (eight of 27) of non-AIDS HIV-positive patients (P less than .05). Patients diagnosed with CIN had significantly lower CD4 cell counts (221/mm3 versus 408/mm3; P less than .06) and CD4:CD8 ratios (0.33 versus 0.62; P less than .02) than those without CIN. Patients with cervicitis had greater T-cell immunosuppression than did those with normal histology. In addition, patients with AIDS were more likely to have higher-grade lesions than were non-AIDS HIV-seropositive patients. Seven of 12 CIN specimens available for analysis by polymerase chain reaction using consensus sequence primers detected human papillomavirus (HPV) DNA, including three patients with three or more HPV types. Our data suggest that abnormal cervical pathology is common among HIV-positive women and that cytologic screening is not predictive of CIN in this population. In addition, the presence and severity of cervical dysplasia correlates with quantitative T-cell function. We strongly recommend that cervical colposcopy be part of the routine management of HIV-seropositive women.

Abstract: Inflammatory bowel disease (IBD) is an idiopathic chronic inflammatory disease of the gastrointestinal system. The spectrum is of predominantly two types, namely, ulcerative colitis and Crohn’s disease. The incidence of IBD has been increasing steadily since 1990, and so the number of agents used in their treatment. Biologics that are derived partly or completely from living biological sources such as animals and humans have become widely available, which provide therapeutic benefits to the IBD patients. Currently, monoclonal antibodies against tumor necrosis factor-alpha (infliximab, adalimumab, certolizumab, and golimumab), integrins (vedolizumab and natalizumab), and interleukin (IL)-12 and IL-23 antagonists (ustekinumab) are approved for use in IBD. Biosimilars of infliximab and adalimumab are also available for the treatment of IBD. This review summarizes the clinical pharmacology, studies leading to their approval, overall indications and their use in IBD, usage in pregnancy and lactation, and the adverse effects of these agents. This review also summarizes the recent advances and future perspectives specific to biologics and biosimilars in IBD. Keywords: inflammatory bowel disease, Crohn’s disease, ulcerative colitis, biologics, biosimilars, tumor necrosis factor, integrin, interleukin, adalimumab, Humira ® , certolizumab, Cimzia ® , golimumab, Simponi ® , infliximab, Remicade ® , vedolizumab, Entyvio, natalizumab, Tysabri ® , ustekinumab, Stelara ®